Good Life Meds Told to Drop Tirzepatide Claims

An advertising review panel recommended the telehealth company stop making health benefit and personalization claims for its compounded tirzepatide products.

Updated on Nov. 4, 2026 in Diabetes

Good Life Meds Told to Drop Tirzepatide Claims

Live Poll

Would you trust a telehealth ad for compounded weight-loss drugs over your doctor's advice?

The National Advertising Division, part of BBB National Programs, recommended that Good Life Meds discontinue health benefit and personalization claims for its compounded Tirzepatide+ products after a challenge from Eli Lilly and Company. Good Life Meds voluntarily and permanently discontinued certain express and implied claims during the inquiry.

Why it matters

The ruling finds the company lacked a reasonable basis for its weight loss and wellness claims, and that its personalization claims overstated individualization. For consumers considering compounded versions of prescription weight loss drugs, the decision highlights that such products are not evaluated in the same way as FDA-approved medications.

The challenge was brought by Eli Lilly against a compounded product, and the cited evidence came from studies of the FDA-approved drug rather than the compounded version. No safety evidence for combining tirzepatide with the product's additives was found in the record.

The players

Eli Lilly and Company

Eli Lilly is a pharmaceutical company that manufactures Mounjaro and Zepbound, the only tirzepatide-based medications approved by the FDA for Type 2 diabetes and chronic weight management.

BBB National Programs

BBB National Programs is a nonprofit self-regulatory organization whose National Advertising Division reviews national advertising for truthfulness and accuracy.

The details

Good Life Meds operates an online telehealth platform that connects consumers with healthcare professionals and pharmacies to sell prescription weight loss medications. The challenged claims said the product supports healthy weight loss, provides natural energy boosts, improves blood sugar control, and preserves lean muscle mass. The FDA's decision to permit compounding during drug shortages did not substantiate those claims.

November 4, 2026: NAD recommendation announced and press release issued

Big Picture

The ruling shows the limits of the FDA's decision to allow compounding of tirzepatide during drug shortages, which did not by itself substantiate health claims made for compounded versions. Compounded products of this kind have drawn scrutiny because they are not the FDA-approved drugs that the cited clinical evidence describes.

Consumers weighing compounded tirzepatide products should know that the health benefit claims were found to lack a reasonable basis in the record reviewed. Anyone considering such a product should consult a healthcare professional about whether it is appropriate for them.

The takeaway

Compounded versions of prescription drugs are not the same as the FDA-approved products their evidence describes, and advertising claims for them can be challenged. Readers should verify health claims against the approved product's labeling before relying on them.